Analysts at StockNews.com initiated coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Get Free Report) (TSE:AEZ) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Aeterna Zentaris Price Performance
Aeterna Zentaris stock opened at $3.71 on Tuesday. Aeterna Zentaris has a fifty-two week low of $3.96 and a fifty-two week high of $12.00. The firm’s 50 day simple moving average is $4.47 and its 200-day simple moving average is $6.12. The company has a market cap of $6.65 million, a P/E ratio of -0.25 and a beta of 1.55.
Aeterna Zentaris Company Profile
Featured Stories
- Five stocks we like better than Aeterna Zentaris
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- The 3 Best Fintech Stocks to Buy Now
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Breakout Stocks: What They Are and How to Identify Them
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.